Mira launches tool to predict menopause and monitor fertility

The US Food and Drug Administration (FDA) has approved Mira’s new hormone tracker as an over-the-counter tool to predict menopause and evaluate fertility.

The Ovum Wand is an AI-powered device that provides accurate detection of the follicle-stimulating hormone (FSH) in urine to help monitor fertility and find possible causes of reproductive issues for women after 35.

From October, the product will be available to US customers. The tool aims to help women get an inside look into their full menstrual cycle, manage irregular cycles, PCOS, and hormone imbalances as well as monitor hormone levels for fertility treatments such as IVF and IUI.

Menopause has been a taboo subject for many generations. Studies have shown that one third of women do not research the topic before they experience menopause.

A survey of 1,039 American women aged 40-65 has found that 45 per cent did not know the distinction between perimenopause and menopause.

Mira, a mobile health platform for monitoring reproductive health, is hoping that its Ovum Wand will provide information to help women understand these life stages and address the symptoms early.

Tracking the FSH is essential for women in their 20s, 30s, or 40s because it directly impacts their ability to get pregnant. To predict approaching menopause or track changes in fertility, a person needs to test over several days for two or more cycles.

Additionally, FSH tracking could also help monitor the effectiveness of hormone replacement therapy (HRT) to make it more targeted and personalised.

Mira allows users to safely monitor their FSH levels at home without the need for a blood test. Data points are saved and analysed to give personalised health insights and the users can also share the information with their medical provider.

“The Mira Ovum Wand further expands our capabilities in at-home hormone testing,” says Sylvia Kang, Mira CEO. “The launch reinforces Mira’s goal to support women throughout their lives by helping them understand their hormones at any age, be it puberty, adulthood, or later years.”

She adds: “This knowledge grants the ability to make informed fertility decisions and eliminates the dread associated with the word ‘menopause’, so that women can go through this journey with confidence and awareness.”

The company offers a line of hormone test wands. Like its predecessors, the new Ovum Wand is compatible with the Mira’s analyser and uses machine learning to track changing hormone patterns over time. The analyser can be connected to Mira App to display clear numerical data along with personalised insights on the user’s reproductive health.

For more info, visit miracare.com.